Chase H&Q 19th Annual Healthcare Conference to Webcast Alkermes' New Corporate Presentation.

Business Editors & Health/Medical Writers

CAMBRIDGE, Mass.--(BW HealthWire)--Jan. 8, 2001

Alkermes, Inc. (NASDAQ: ALKS) announced today that its new corporate presentation will be webcast by the Chase H&Q Healthcare Conference live on Wednesday, January 10 at 9:30am PDT. Investors may access the webcast at www.chasehq.com, under the "Events" tab.

Richard Pops, chief executive officer of Alkermes, Inc., will review the company's progress and deliver an overview of its anticipated 2001 milestones. His presentation will be delivered at 9:30am PDT on Wednesday, January 10, from the Colonial room of the Westin St. Francis Hotel in San Francisco.

Alkermes is a leader in the development of products based on sophisticated drug delivery technologies. Its first product, Nutropin Depot(TM), is a long-acting form of Genentech's recombinant human growth hormone using Alkermes' ProLease(R) technology. The company has several areas of focus, including (i) controlled, sustained release of injectable drugs lasting several days to several weeks, utilizing its ProLease(R) and Medisorb(R) technologies and (ii) the development of pharmaceutical products based on proprietary pulmonary drug delivery technologies utilizing its AIR(TM) technology. In addition to its Cambridge, Massachusetts headquarters, research and manufacturing facilities, Alkermes operates research and manufacturing facilities in Ohio and a medical affairs office in Cambridge, England.

Certain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Alkermes believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurance that: (i) clinical trials of the company's product candidates will be successful, completed on a timely basis, or at all, (ii) the company's partners will continue development of any product candidate to the point of receiving marketing approval from regulatory authorities, or (iii) the company's product candidates will be commercialized successfully.

Alkermes' business is subject to significant risks and there can be no assurance that actual results of the company's development activities and its results of operations will not differ materially from its expectations. For information with respect to other factors which could cause actual results to differ from expectations, reference is made to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.